What do systematic reviews say?

Urtoxazumab (3.0 mg/kg) vs placebo

It is very uncertain whether urtoxazumab (3.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  RR 0.34 [0.01, 8.14]
  1 study · 71 participants
  Very low

Urtoxazumab (1.0 mg/kg) vs placebo

It is very uncertain whether urtoxazumab (1.0 mg/kg) changes incidence of HUS compared with placebo (very low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.06, 14.59]
  1 study · 74 participants
  Very low

Urtoxazumab (1.0 mg/kg) vs placebo

Urtoxazumab (1.0 mg/kg) showed no clear difference in adverse events ‐ treatment emergent compared with placebo (low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.79, 1.13]
  1 study · 74 participants
  Low

Urtoxazumab (1.0 mg/kg) vs placebo

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 74 participants
  Low

Urtoxazumab (1.0 mg/kg) vs placebo

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Urtoxazumab (1.0 mg/kg) vs placebo

It is very uncertain whether urtoxazumab (1.0 mg/kg) changes neurological complications compared with placebo (very low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  RR 2.84 [0.31, 26.08]
  1 study · 74 participants
  Very low

Urtoxazumab (1.0 mg/kg) vs placebo

It is very uncertain whether urtoxazumab (1.0 mg/kg) changes death (any cause) compared with placebo (very low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  RR 0.95 [0.06, 14.59]
  1 study · 74 participants
  Very low

Antibiotics vs no treatment

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antibiotics vs no treatment

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antibiotics vs no treatment

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bovine colostrum vs placebo

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low

Bovine colostrum vs placebo

It is very uncertain whether bovine colostrum changes adverse events compared with placebo (very low certainty).

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  RR 0.92 [0.42, 2.03]
  1 study · 27 participants
  Very low

Bovine colostrum vs placebo

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bovine colostrum vs placebo

The review found no eligible studies for this question.

• Interventions for preventing diarrhoea‐associated haemolytic uraemic syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

CVVHD vs CVVH or CVVHDF

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pre‐dilution vs post‐dilution (as defined by study investigators)

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pre‐dilution vs post‐dilution (as defined by study investigators)

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pre‐dilution vs post‐dilution (as defined by study investigators)

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Higher blood flow vs standard blood flow

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 499 participants
  Low

Higher blood flow vs standard blood flow

The review found no eligible studies for this question.

• Non‐pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found